BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress
BioCardia (NASDAQ: BCDA) will present at the CSI Focus Devices in Heart Failure congress in Frankfurt, Germany.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCardia (NASDAQ: BCDA) will present at the CSI Focus Devices in Heart Failure congress in Frankfurt, Germany.
Peter Altman, PhD, President and CEO, will deliver an invited presentation titled “Intramyocardial Cell Therapy for Ischemic Heart Failure of Reduced Ejection.” The session is on Friday, December 5, 2025, during the Myocardial structural therapies targeting the ventricles session from 10:30–11:30 CET.
Details
News Market Reaction – BCDA
On Dec 1, the day this news came out, BCDA closed 4.14% below the previous close.
Data tracked by StockTitan Argus for the Dec 1 session.
Key Figures
- Conference day
- Friday, December 5
- CSI Focus Devices in Heart Failure session date
- Session time
- 10:30 - 11:30 CET
- Myocardial structural therapies targeting the ventricles session
- Current price
- $1.47
- Price before publication of CSI Focus presentation news
- 52-week range
- $1.00 – $3.20
- Stock trading <b>-54.06%</b> vs 52-week high pre-news
Historical Context
-
New director elected as experienced industry leader replaces outgoing member.
-
Announcement of invited presentation at CSI Focus heart failure congress.
-
Appointment of VP of Quality with extensive regulatory experience.
-
Q3 results, financing, trial progress, and cash runway into Q2 2026.
-
First patient enrolled in Phase 3 CardiAMP HF II heart failure trial.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
intramyocardial medical
ischemic medical
cardiac output medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it will participate at the CSI Focus Devices in Heart Failure this week in Frankfurt, Germany. BioCardia’s President and Chief Executive Officer, Peter Altman, PhD, will make an invited presentation entitled, “Intramyocardial Cell Therapy for Ischemic Heart Failure of Reduced Ejection.”
| Meeting: | CSI Focus– Devices therapies in Heart Failure (D-HF) |
| Day: | Friday, December 5th |
| Session: | Myocardial structural therapies targeting the ventricles |
| Time: | 10:30 - 11:30 CET |
CSI Focus D-HF provides a comprehensive overview of device-based therapy in heart failure, including advancements in ventricle restoration strategies, device-based strategies to improve cardiac output, monitoring systems, and other cutting edge technologies and emerging platforms in this new field. For more information see: https://www.csi-congress.org/dhf.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit: https://www.BioCardia.com.
Forward Looking Statements
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to our presentation to be made at CSI-Focus D-HF. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.
We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 26, 2025, under the caption titled “Risk Factors,” and in our subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Media Contact: Miranda Peto, Investor Relations Email: mpeto@BioCardia.com Phone: 650-226-0120 Investor Contact: David McClung, Chief Financial Officer Email: investors@BioCardia.com Phone: 650-226-0120
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.